GlassScriptPhysician profile
Ross M Nesbit
NPI 1386870475
$452,285.23
in general payments reported to CMS, 2019-2025
34 companies · $62K in 2025
The $62K reported for 2025 was more than what 99% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $25K · 2021: $82K · 2022: $109K · 2023: $56K · 2024: $69K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115K · Honoraria: $50K · Food and Beverage: $8,885 · Travel and Lodging: $8,594 · Consulting Fee: $5,495 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,591.00 |
| Honoraria | $50,112.50 |
| Food and Beverage | $8,885.42 |
| Travel and Lodging | $8,593.89 |
| Consulting Fee | $5,494.56 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $130,156.22 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $111,627.01 | 2019-2025 | Veltassa, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $101,485.21 | 2021-2025 | |
| Calliditas Therapeutics US INC. | $58,526.59 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $22,406.56 | 2019-2025 | Vafseo, Auryxia |
| Aurinia Pharma U.S., INC. | $17,986.47 | 2021-2025 | Lupkynis |
| Amgen INC. | $1,363.95 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Janssen Pharmaceuticals, INC | $1,315.00 | 2020-2021 | |
| Scpharmaceuticals INC. | $1,217.14 | 2024-2025 | |
| Cipla USA INC. | $1,000.22 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $773.87 | 2020-2025 | Acthar, Terlivaz |
| Travere Therapeutics, INC. | $660.03 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $622.93 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $452.69 | 2019-2025 | Velphoro, Velphoro |
| Alexion Pharmaceuticals, INC. | $443.67 | 2019-2025 | Ultomiris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $346.52 | 2020-2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $271.60 | 2019 | |
| Novartis Pharmaceuticals Corporation | $269.54 | 2023-2025 | |
| Daiichi Sankyo INC. | $256.91 | 2019-2023 | Injectafer |
| Opko Pharmaceuticals, LLC | $226.74 | 2019-2022 | |
| Genzyme Corporation | $179.51 | 2019-2024 | |
| Glaxosmithkline, LLC. | $124.72 | 2020-2023 | Jesduvroq |
| Shire North American Group INC | $113.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.03 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $62.18 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $61.26 | 2022-2023 | Purified Cortrophin Gel |
| Lilly USA, LLC | $49.62 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $44.77 | 2019 | |
| Baxter Healthcare | $44.51 | 2019-2023 | Renal - Acute |
| Kyowa Kirin, INC. | $36.10 | 2024 | Crysvita |
| Ardelyx, INC. | $33.36 | 2024 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $22.53 | 2025 | Empaveli |
| Lundbeck LLC | $21.17 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Nesbit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.